Drugs / BX-U001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03828344 | Dec 2026 → Dec 2027 expected | rheumatoid arthritis | Baylx Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04452097 | Jun 2026 → Jul 2027 | COVID-19, acute respiratory distress syndrome | Baylx Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BX-U001 | “The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of a human...” NCT04452097 ↗1“allogeneic fresh human umbilical cord tissue-derived mesenchymal stem cell product BX-U001” NCT03828344 ↗ |
| Known as | hUC-MSC suspension | “BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10\^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.” NCT03828344 ↗ |
| Modality | Cell therapy | “allogeneic fresh human umbilical cord tissue-derived mesenchymal stem cell product BX-U001” NCT03828344 ↗ |
| Route | Intravenous | “given by IV infusion” NCT03828344 ↗ |